Overview

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Status:
Active, not recruiting

Trial end date:
2041-07-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with high-risk localized prostate cancer (with a stringent selection of patients with at least 2 high-risk features), in a 2 by 2 factorial trial.

Phase:

Phase 3

Details

Lead Sponsor:

UNICANCER

Collaborator:

Sanofi

Treatments:

Androgens